secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001104659-24-116413
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Replimune reports Q2 FY2025 net loss $53.1M; BLA for RP1 in melanoma on track before year-end
--------------------------------------------------------------------------------

- Completed pre-BLA meeting with FDA; BLA submission for RP1+nivolumab in anti-PD1 failed melanoma via accelerated approval path on track by end of 2024.
- IGNYTE primary analysis: 33.6% ORR at 12 months by modified RECIST 1.1; median DOR from response initiation 21.6 months.
- Cash, cash equivalents and short-term investments $432.1M as of Sep 30, 2024; funding operations into H2 2026.
- R&D expenses $43.4M, down from $49.1M; net loss $53.1M, improved from $60.0M YoY.
- RP2 in uveal melanoma: registration-directed trial with first patient enrollment expected Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465924116413/0001104659-24-116413-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465924116413/tm2428095d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-116413

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer